Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

NCT06144385 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06144385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06144385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 24, 2022
Completion date
December 31, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic cell carcinoma, liver carcinoma